Abstract
No public abstract is available from the verified source records.
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
First-line serplulimab in extensive-stage small cell lung cancer: secondary analysis of the ASTRUM-005 phase 3 randomized clinical trial.
10.1001/jamaoncol.2026.1645 · 2026
No additional external references are available.